FDA Releases New Draft Guidance Regarding Clinical Trial Data Monitoring Committees

The U.S. Food & Drug Administration (FDA) released a new proposed draft guidance in February that would change the FDA’s outlook on the engagement of a data monitoring committee (DMC) in clinical trials. Originally Published in Birmingham Medical News….
By: Burr & Forman
Previous Story

[Podcast] Biotechnology, Chemical and Pharmaceutical: Supreme Showdown

Next Story

The DOL’s New Guidance for AI and its Impact in the Workplace